Moderna Inc. (MRNA)
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Moderna's shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some changes to its strategy -- and a key goal.
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Thursday, Moderna Inc MRNA unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.
Moderna, Inc. Class Action: Levi & Korsinsky Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 – MRNA
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
Shares of Moderna (MRNA) fell for the second day in a row after the company said it would slash its research and development expenditures.
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRNA
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRNA
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv- 12058, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Moderna securities between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
October 8, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - MRNA
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna's spending cuts, pipeline shakeup leave doubts about a rebound, analysts say
Moderna's cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of downgrades as analysts focused on longer timelines to launch some products and questioned when the company can return to profitability.
Moderna Inc May Have Violated Securities Laws And Affected Stockholders Are Urged To Contact The Schall Law Firm About A Suit
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Tradepulse Power Inflow Alert: Moderna Inc. Rises 8.9% On The Trading Day
MRNA RECEIVES SIGNAL AT 10:21 AND RISES THROUGHOUT THE DAY
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development (R&D) budget by about 20% over the next three years, a result of low sales projections and poor vaccine sales.
